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Key Points
Question
Does the addition of the immune checkpoint inhibitor pembrolizumab to standard neoadjuvant
chemotherapy improve efficacy in early-stage, high-risk, ERBB2 (formerly HER2)-negative breast cancer?
Findings
In this analysis of the adaptively randomized phase 2 I-SPY2 trial, including 250 women with early-stage
breast cancer, the addition of pembrolizumab to standard neoadjuvant chemotherapy more than doubled
complete pathologic response rates compared with chemotherapy alone for both hormone receptor-
positive/ERBB2-negative, and triple-negative breast cancer.
Meaning
These results from the I-SPY2 trial suggest that there is a greater than 99% predictive probability that
pembrolizumab plus neoadjuvant chemotherapy will be significantly better than chemotherapy alone in a
phase 3 randomized clinical trial in ERBB2-negative breast cancer.
Abstract
Importance
Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy
experience a recurrence within 5 years. Improvements in therapy are greatly needed.
Objective
To determine if pembrolizumab plus neoadjuvant chemotherapy (NACT) in early-stage breast cancer is
likely to be successful in a 300-patient, confirmatory randomized phase 3 neoadjuvant clinical trial.
Design, Setting, and Participants
The I-SPY2 study is an ongoing open-label, multicenter, adaptively randomized phase 2 platform trial for
high-risk, stage II/III breast cancer, evaluating multiple investigational arms in parallel. Standard NACT
serves as the common control arm; investigational agent(s) are added to this backbone. Patients with
ERBB2 (formerly HER2)-negative breast cancer were eligible for randomization to pembrolizumab
between November 2015 and November 2016.
Interventions
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Participants were randomized to receive taxane- and anthracycline-based NACT with or without
pembrolizumab, followed by definitive surgery.
Main Outcomes and Measures
The primary end point was pathologic complete response (pCR). Secondary end points were residual
cancer burden (RCB) and 3-year event-free and distant recurrence-free survival. Investigational arms
graduated when demonstrating an 85% predictive probability of success in a hypothetical confirmatory
phase 3 trial.
Results
Of the 250 women included in the final analysis, 181 were randomized to the standard NACT control
group (median [range] age, 47 [24.77] years). Sixty-nine women (median [range] age, 50 [27-71] years)
were randomized to 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by AC; 40
hormone receptor (HR)-positive and 29 triple-negative. Pembrolizumab graduated in all 3 biomarker
signatures studied. Final estimated pCR rates, evaluated in March 2017, were 44% vs 17%, 30% vs 13%,
and 60% vs 22% for pembrolizumab vs control in the ERBB2-negative, HR-positive/ERBB2-negative, and
triple-negative cohorts, respectively. Pembrolizumab shifted the RCB distribution to a lower disease
burden for each cohort evaluated. Adverse events included immune-related endocrinopathies, notably
thyroid abnormalities (13.0%) and adrenal insufficiency (8.7%). Achieving a pCR appeared predictive of
long-term outcome, where patients with pCR following pembrolizumab plus chemotherapy had high
event-free survival rates (93% at 3 years with 2.8 years’ median follow-up).
Conclusions and Relevance
When added to standard neoadjuvant chemotherapy, pembrolizumab more than doubled the estimated pCR
rates for both HR-positive/ERBB2-negative and triple-negative breast cancer, indicating that checkpoint
blockade in women with early-stage, high-risk, ERBB2-negative breast cancer is highly likely to succeed





The immune system is regulated by a delicate balance of factors that initiate antitumor immune responses
and inhibit excessive inflammation and autoimmunity. Cells from both the innate and adaptive immune
systems work to eradicate pathogens and other threats, including cancer. A number of investigations
over the past decade suggest that a proportion of breast cancers are immunogenically active and that some
breast tumors have a substantial lymphocytic infiltrate. Lymphocyte-predominant breast cancers are
characterized by tumor-infiltrating lymphocytes comprising 50% or more of the tumor bed. Primary breast
tumors with a robust immune infiltrate are associated with a better response to neoadjuvant chemotherapy.
Programmed cell death ligand-1 (PD-L1) is expressed on the surface of multiple types of cells, including
tumor and infiltrating immune cells. Programmed cell death protein-1 (PD-1) is expressed primarily on T
cells. Programmed cell death protein-1 interacts with its ligands (PD-L1 and PD-L2) and directly inhibits
apoptosis of tumor cells, and promotes peripheral T effector cell exhaustion and the conversion of T
effector cells to immunosuppressive T regulatory cells. Pembrolizumab (MK-3475, Keytruda, Merck) a
highly selective, humanized IgG4 monoclonal antibody specific for PD-1, is US Food and Drug
Administration (FDA)-approved for use in a number of advanced malignant diseases.
1,2,3
4
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Pembrolizumab has been investigated as monotherapy for the treatment of advanced triple-negative breast
cancer (TNBC) and hormone receptor (HR)-positive breast cancer. Initial studies have reported low
response rates in previously treated, advanced HR-positive and TNBC (12% and 4.8%-18.5%,
respectively).  KEYNOTE 086-cohort B reported a monotherapy response rate of 23% in previously
untreated, PD-L1–positive, advanced TNBC. Adams and colleagues  reported that anthracycline- or
taxane-based chemotherapy in this setting had a rate of 23%. Although the response rates are similar in the
frontline setting, the duration of response with immunotherapy is longer.
Based on a 2018 meta-analysis,  24.9% of those with early-stage breast cancer who receive (neo)adjuvant
therapy had a distant recurrence by 5 years. The promising efficacy observed with single-agent checkpoint
blockade for advanced ERBB2 (formerly HER2)-negative breast cancer, and the considerable benefits
observed with PD-1 inhibitors combined with chemotherapy for lung cancer and other malignant diseases,
led us to evaluate the efficacy of adding pembrolizumab to standard neoadjuvant chemotherapy in the I-
SPY2 trial, with the hypothesis that immune-targeted agents would be more effective in the early-stage
setting when the immune system is less likely to be compromised.
Methods
Study Design
The I-SPY2 study is an ongoing, multicenter, open-label, adaptively randomized phase 2 multicenter trial
of neoadjuvant chemotherapy (NACT) for early-stage breast cancer at high risk of recurrence
(NCT01042379).  It is a platform trial evaluating multiple investigational arms in parallel, each
consisting of standard NACT (serving as the common control arm) plus an investigational
agent/combination. The primary end point is pathologic complete response (pCR), defined as the absence
of invasive tumor in breast and regional nodes at the time of surgery. The primary analysis is modified
intention to treat, where participants receiving allocated therapy are considered evaluable; participants who
switch to nonprotocol assigned therapy, forgo surgery, or withdraw from the trial are considered “non-
pCR” during analysis. Secondary end points include residual cancer burden (RCB), 3-year event-free
survival (EFS), and distant relapse-free survival (DRFS). All patients are followed up for long-term
outcome and safety.
Biomarker assessments performed at baseline are used to classify patients into 1 of 8 subtypes based on
HR, ERBB2-receptor, and MammaPrint status.  Adaptive randomization in I-SPY2 preferentially assigns
patients to agents according to Bayesian probabilities of rates of pCR for each subtype; 20% of patients are
randomly assigned to control.
Agents graduate from I-SPY2 by reaching, in any of the 10 clinically relevant signatures, a predefined
efficacy threshold of 85% probability of success in a subtype-specific, hypothetical 300-patient, 1-to-1
confirmatory phase 3 trial.  Agents may be dropped for futility if the predicted probability of success
in phase 3 is less than 10% for all signatures or the maximum enrollment threshold is reached for that arm.
Graduation probabilities for each actively enrolling arm are continually updated using a longitudinal model
based on change in tumor volume by magnetic resonance imaging (MRI, for those still undergoing
treatment) and pathologic response for those that have completed surgical therapy. Additional details on
the study design have been published previously.  The trial protocol and protocol amendments are
available in Supplement 1.
Eligibility
Patients eligible for I-SPY2 are women aged 18 years or older, with stage II or III breast cancer and
primary tumors larger than 2.5 cm by clinical examination or larger than 2.0 cm by imaging, and Eastern
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positive, ERBB2-negative disease are excluded from I-SPY2 because their lower risk of recurrence does
not justify escalation of therapy.  All patients provide written informed consent prior to screening and
again after randomization. Only ERBB2-negative patients were eligible for randomization to the
pembrolizumab arm.
Treatment
Participants in the control arm received standard NACT: 80 mg/m  intravenous paclitaxel weekly for 12
weeks, followed by 4 cycles of 60 mg/m  doxorubicin plus 600 mg/m  intravenous cyclophosphamide
every 2 to 3 weeks (AC). Participants in the pembrolizumab arm received standard NACT plus 200 mg
intravenous pembrolizumab every 3 weeks for 4 cycles (weeks 1, 4, 7, and 10) concurrently with
paclitaxel. Steroid premedication was standardized across sites. For the first infusion, pembrolizumab was
given first, followed by 20 mg of dexamethasone received orally after a 30-minute waiting period,
followed by paclitaxel 30 minutes later. If no infusion reaction occurred, dexamethasone was reduced to 10
mg for week 2. If participants did not experience an infusion reaction with the first 2 doses of paclitaxel,
dexamethasone was discontinued. If patients had an infusion reaction despite corticosteroid
premedications, switching to nab-paclitaxel was allowed. If infusion reactions were manageable with
dexamethasone, the premedications remained unchanged.
Definitive surgery followed AC, with lumpectomy or mastectomy at the discretion of the treating surgeon.
Sentinel node dissection was allowed in patients with node-negative disease, with axillary node dissection
in patients with node-positive disease according to National Comprehensive Cancer Network (NCCN) and
local practice guidelines.  Adjuvant treatment was not mandated by the trial, but was at the discretion of
the treating oncologist. However, standard-of-care adjuvant therapy per NCCN guidelines was
recommended.
Assessments
Core biopsies and breast MRIs were performed at baseline and following 3 weeks of therapy. Additional
MRIs were performed between paclitaxel and AC and again following AC, as previously described.
Surgical specimens were analyzed for response by local pathologists trained to assess residual cancer
burden (RCB).  Biomarkers assessed include the 70-gene MammaPrint  and TargetPrint ERBB2 gene
expression assays  using the 44K full-genome microarray (Agendia).
Trial Oversight
The trial was designed by the I-SPY2 study investigators. Merck provided study drug but played no role in
the study design, collection/analysis of data or manuscript preparation. All participating sites received
institutional review board approval, and patients provided written informed consent. The I-SPY2 DSMB
meets monthly to review patient safety and study progress.
Statistical Analysis
In the standard I-SPY2 Bayesian approach, probability distributions of pCR rate for each regimen in each
subtype are updated continuously via a covariate analysis with HR, ERBB2, and MP status as covariates,
adjusting for time trends to allow comparisons against all enrolled I-SPY2 controls prior to the date
randomization was stopped for the investigational arm (eMethods in Supplement 2). Adaptive
randomization probabilities and the Bayesian probability that each regimen is superior to control are
derived from these distributions. Graduation of a treatment arm occurs if the predicted pCR rate in any
signature meets the prespecified threshold of 85% probability of success in a hypothetical 300-patient, 1-
to-1 randomized, phase 3 trial.  Final end point analysis was completed after all participants completed
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Kaplan-Meier survival curves for each arm were generated, with hazard ratios (HRs) by Cox proportional
hazard modeling. Twenty-six of the 172 controls included in this exploratory analysis were concurrently
randomized with pembrolizumab and no adjustments for time trends were made. Statistics regarding this
exploratory EFS analysis, assessed in March 2019, are descriptive only because sample sizes were small
and I-SPY2 is not powered for EFS or other survival end points.
Results
Patient Population
Patients with ERBB2-negative breast cancer who enrolled in I-SPY2 between November 26, 2015, and
November 5, 2016, were eligible for randomization to pembrolizumab. A total of 69 patients were
adaptively randomized to pembrolizumab and were evaluable for the primary end point (40 HR-
positive/ERBB2-negative, 29 TNBC). The contemporary control population for the primary efficacy
analysis consisted of 181 patients randomized to the control arm who received their allocated treatment
from the opening of I-SPY2 enrollment on March 30, 2010 until November 5, 2016 (Figure 1). Baseline
characteristics were similar between the pembrolizumab and control arms (eTable in Supplement 2).
Twenty patients in the control arm did not proceed with their allocated assignment. Two patients on
pembrolizumab and 7 in the control arm did not proceed to surgery; all 9 were counted as non-pCR.
Efficacy
After 69 patients were randomized to the intervention arm, pembrolizumab achieved the prespecified
graduation threshold (≥85% likelihood of predictive probability of success in a phase 3 trial) for all 3
signatures studied. When pembrolizumab reached the graduation threshold based on MRI models in the 3
signatures, randomization to the arm was halted. Once patients completed surgery and RCB was assessed,
the final predictive probabilities were generated, as reported in Table 1. Probability distributions for
achieving pCR are shown in eFigure 1A in Supplement 2, and the distribution of patients by RCB are
shown in eFigure 1B in Supplement 2. Estimated pCR rates for ERBB2-negative, HR-positive/ERBB2-
negative, and TNBC signatures in the pembrolizumab arm were 44%, 30%, and 60%, compared with 17%,
13%, and 22% in the control populations, respectively. A lower percentage of patients in the
pembrolizumab arm had RCB-III at the time of surgery compared with control; no patients with TNBC in
the pembrolizumab arm had RCB-III (eFigure 1B in Supplement 2). Nine patients (2 in the
pembrolizumab and 7 in the control arm) did not proceed to surgery and are not included in the RCB
analysis (eFigure 1B in Supplement 2).
Six patients in the pembrolizumab arm either progressed or did not respond to treatment; pembrolizumab
was discontinued and carboplatin was administered to 3 of these 6. These patients were counted as non-
pCR to protocol-directed therapy regardless of their final pathologic response.
Participants in the pembrolizumab (n = 66) and control (n = 172) arms who had follow-up data as of
February 26, 2019, were included in an exploratory EFS analysis (Figure 2) (eFigure 2 in Supplement 2).
Median follow-up times for patients in the pembrolizumab and control arms were 2.8 and 3.5 years,
respectively; only 4 of 69 patients randomized to pembrolizumab had 3 or more years of follow-up.
Qualitatively similar EFS was observed between the pembrolizumab and control arms for the overall
cohort (Figure 2), although caution must be emphasized in drawing conclusions owing to the small number
of patients. Patients who achieved pCR had excellent outcomes regardless of arm.
Safety and Toxic Effects
All patients who received at least 1 dose of study-assigned therapy were evaluable for safety and toxic
effects. Selected clinically relevant adverse events reported within 180 days of the last investigational
agent dose (pembrolizumab for investigational arm and paclitaxel for control arm) are summarized in 
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Table 2. The most notable differences in adverse events between the arms were in the incidence of
immune-related adverse events (irAEs), most of which were grade 1 to 2 and treated per protocol with
dose interruption or steroid therapy. Adverse events observed in the pembrolizumab plus chemotherapy
arm were consistent with the known safety profile of each component; no new safety concerns were
identified. The most common irAEs reported were endocrinopathies, with thyroid dysfunction being the
most common (hypothyroidism and hyperthyroidism), occurring in 9 of the 69 patients who received
pembrolizumab (13.0%). Adrenal insufficiency (AI) was observed in 6 of the 69 patients who received
pembrolizumab (8.7%), with 5 of these irAE occurring more than 30 days after last dose of
pembrolizumab. Three of the cases of AI were classified as hypophysitis and 1 as primary adrenal
insufficiency; in the remaining 2 cases determination of primary vs secondary AI was not possible owing
to initiation of steroid therapy prior to completion of workup. A number of irAEs, with the exception of
pruritus, occurred more than 30 days after the final dose of pembrolizumab. These irAEs were successfully
treated per protocol with dose interruption or steroids, and no irAE fatalities were observed.
Discussion
We describe results from the I-SPY2 study arm examining immune checkpoint blockade in combination
with chemotherapy for high-risk, early-stage ERBB2-negative breast cancer. The addition of 4 cycles of
pembrolizumab to standard-of-care NACT more than doubled estimated pCR rates in all biomarker
signatures studied. Notably, pembrolizumab was the first agent of 10 studied to graduate in the HR-
positive/ERBB2-negative signature since I-SPY2 opened in 2010.
The pCR rates in the I-SPY2 control population have been stable over time, but are lower than reported in
other neoadjuvant studies.  I-SPY2 is an unblinded study where both patients and physicians are aware of
treatment assignment; analysis is intention to treat. Treating physicians concerned about poor response
may modify the treatment regimen (eg, add carboplatin to the paclitaxel portion of treatment); these cases
are counted as non-pCR regardless of response, due to nonadherence to study assignment. Three patients
in the pembrolizumab arm and 11 patients in the control arm who received neoadjuvant carboplatin were
classified as non-pCR. It should be emphasized that the estimated pCR rates that are the reporting standard
in I-SPY2 are different than pCR rates reported from the studies using a typical randomized clinical trial
design. The estimated pCR rate represents the mean of the final posterior probability distribution for pCR
in a given subtype, using a model adjusting for subtype and time trend. In this study, actual (raw) rates of
pCR, (the standard for reporting in a typical randomized clinical trial), were higher than the estimated
rates, but may be biased owing to the adaptive randomization procedure that favors regimens and subtypes
exhibiting better response. The comparative estimated pCR rates between the experimental and control
arms provide perspective on the potential impact of an individual therapy in a given subtype. However, it
is important to bear in mind that I-SPY2 is a phase 2 study designed to rapidly screen for agents that are
likely to succeed in phase 3 trials. In this respect, preliminary reports from the phase 3 KEYNOTE 522
study provide strong validation of this approach.
Initial concerns that steroid premedications required for paclitaxel might interfere with the efficacy of
pembrolizumab appear unfounded. Although steroid premedications were discontinued after 2 doses of
(weekly) paclitaxel if no infusion reactions were observed, they were routinely used per physician
discretion for infusion reactions and management of irAEs. Because median time to response with
pembrolizumab monotherapy in advanced breast cancer was reportedly 18 weeks,  there was initial
concern that the 20- to 24-week duration of NACT would be too short to see the benefit of neoadjuvant
pembrolizumab. Although we observed no complete responses on the week 3 MRI, 16 of 31 (52%) of
those who eventually achieved a pCR showed greater than 95% reduction in tumor volume by week 12,
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The addition of pembrolizumab increased irAEs, particularly endocrinopathies. Rates of thyroid
abnormalities (including both hypothyroidism and hyperthyroidism) were similar to published reports with
pembrolizumab, whereas rates of AI were higher.  Adrenal insufficiency (primary and secondary) onset
was typically observed after completion of pembrolizumab, with 5 of 6 patients diagnosed postoperatively,
more than 12 weeks following the last dose of pembrolizumab. Presentation included symptoms of
extreme fatigue, nausea, and emesis. Five patients with AI were hospitalized for evaluation and treatment.
As of this writing, all 6 cases of AI observed in this arm are ongoing; patients are doing well on
replacement therapy. Serial cortisol assessments (not routinely performed at the outset) were instituted on
January 13, 2017, to detect subclinical cases of AI prior to surgery. Half of those who developed AI did so
prior to routine screening, and the other 3 of 6 had presurgical cortisol testing.
The reason for elevated rates of AI in this study is unclear. Of the 6 patients who developed AI, there was
no discernable correlation with clinicopathologic features, including age, stage, HR status, and pCR/RCB
(3 achieved pCR, 3 did not), with the latter equally distributed among RCB-I, RCB-II, and RCB-III (the
patient who achieved RCB-I also received carboplatin owing to suboptimal response). In KEYNOTE 522,
4.5% of patients developed AI (1.8% and 2.7% had primary and secondary AI, respectively). The higher
rates observed in our trial could be related to difference in chemotherapy backbone, aggressive tapering of
steroid premedications, or simply an artifact of small sample size. Regardless, future work to characterize
the risk factors for developing irAEs is warranted, to improve the therapeutic index of these agents.
Limitations
In an exploratory analysis, no significant differences in 3-year EFS were found between the
pembrolizumab and control arms. However, follow-up for the pembrolizumab arm was shorter (median,
2.8 years vs 3.5 years for control), many of the nonresponders received additional therapy, and the study
was underpowered for this end point. This is a limitation of the I-SPY2 approach, where the adaptive
randomization results in fewer patients being required to reach statistical significance compared with
standard randomized clinical trials. Patients with HR-positive/ERBB2-negative disease who failed to
achieve a pCR seemed to do particularly poorly. It is possible that pembrolizumab moves patients to pCR
who would have otherwise had a good EFS outcome despite residual disease and thus the failure to
achieve a pCR in HR-positive/ERBB2-negative disease with the addition of pembrolizumab identifies a
particularly bad prognosis group. It is also possible that pembrolizumab worsens outcome for a subset of
patients in this subtype; the ongoing randomized phase 3 KEYNOTE 756 will further clarify the outcome
of these patients. Most importantly, though, those patients who achieved a pCR regardless of signature had
good outcomes.
Conclusions
The immune checkpoint inhibitor pembrolizumab, when added to standard NACT, was associated with
improvement in pCR rates over chemotherapy alone in women with high-risk, early-stage, ERBB2-
negative breast cancer. Randomized phase 3 registrational trials evaluating pembrolizumab in combination
with standard NACT for TNBC (KEYNOTE 522) and high-risk, HR-positive/ERBB2-negative breast
cancer (KEYNOTE 756) are ongoing. Preliminary reports that the addition of pembrolizumab to standard
NACT in TNBC is associated with improved pCR rates in the KEYNOTE 522 randomized phase 3 trial
provides validation of the I-SPY2 concept, which aims to accelerate drug development by efficiently
identifying effective agents and the signatures in which they are most effective. Future I-SPY2 arms will
continue to build on the promise of checkpoint blockade for women with high-risk, early-stage breast
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Figure 1.
CONSORT Diagram for the Pembrolizumab Arm and Control Arm Populations
I-SPY2 utilizes contemporary controls for analysis purposes, in which the comparator control arm consists of all
patients enrolled to the control arm from the start of I-SPY2 until the close of the specified investigational arm.
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Table 1.
Final Predictive Probabilities of Success of 4 Cycles of Pembrolizumab With Paclitaxel
Followed by Anthracyclines in Phase 3 Testing in the 3 ERBB2 Biomarker Signatures
Biomarker
Signature
Estimated Rate of Pathologic Complete
Response (95% Probability Interval)
Probability, %




Success in Phase 3 Trial
ERBB2
negative




30 (17-43) 13 (7-19) >99.9 99.6
TNBC 60 (44-75) 22 (13-30) 99.6 83.4
Abbreviations: HR, hormone receptor; TNBC, triple-negative breast cancer.
The pembrolizumab regimen graduated in all 3 signatures, based on the predefined efficacy threshold for graduation
(85% probability of success in a 300-patient phase 3 trial). As enrollment to an investigational arm progresses, the
probability of success in a phase 3 trial is continually updated based on longitudinal magnetic resonance imaging
assessments and pathologic responses in patients who have had surgery. Agents graduate and accrual to the
investigational arm closes when the predictive probability of success is 85% or more. The final predicted probability
of success is updated after all patients in the investigational arm have completed surgery, thus graduates can have a
final predictive probability of less than 85%, but are still considered graduates.
a
a
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Figure 2.
Event-Free Survival by Signature and Pathologic Complete Response (pCR)
Event-free survival of the (A) entire ERBB2 (formerly HER2)-negative cohort, (B) triple-negative cohort, and (C)
HR-positive/ERBB2-negative cohort. The blue curves represent patients treated with pembrolizumab and the
orange those treated with control; the dashed lines represent those who achieved a pCR and the solid line those
who did not. Only those individuals who had follow-up information as of the cutoff date of February 26, 2019, are
included in this analysis (66 and 172, in the pembrolizumab [Pembro] and control arms, respectively).
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Table 2.
Selected Adverse Events Reported Within 180 Days of Last Investigational Treatment
(Pembrolizumab for the Investigational Arm and Paclitaxel for the Control Arm)a
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Open in a separate window
Abbreviation: AEs, adverse events.
The number of AEs occurring within 30 days and those occurring between 30-180 days of last dose are reported.
Two patients had both hypothyroidism and hyperthyroidism over the course of their treatment.
Includes primary and secondary causes of adrenal insufficiency (eg, hypophysitis and hypopituitarism).
Includes autoimmune hepatitis and hepatitis.
Event No. (%)
Pembrolizumab (n = 69) Control (n = 181)
Days Total Days Total
<30 30-180 <30 30-180
       
Selected Adverse Events
All grades
Febrile neutropenia 1 (1.4) 5 (7.2) 6 (8.7) 7 (3.9) 6 (3.3) 13 (7.2)
Neutropenia 5 (7.2) 2 (2.9) 7 (10.1) 2 (1.1) 2 (1.1) 4 (2.2)
Anemia 14 (20.3) 9 (13.0) 23 (33.3) 17 (9.4) 18 (9.9) 35 (19.3)
Fatigue 51 (73.9) 9 (13.0) 60 (87) 133 (73.5) 19 (10.5) 152 (84)
Nausea 44 (63.8) 11 (15.9) 55 (79.7) 117 (64.6) 14 (7.7) 131 (72.4)
Vomiting 18 (26.1) 8 (11.6) 26 (37.7) 30 (16.6) 6 (3.3) 36 (19.9)
Diarrhea 29 (42) 10 (14.5) 39 (56.5) 60 (33.1) 10 (5.5) 70 (38.7)
Peripheral motor neuropathy 6 (8.7) 3 (4.3) 9 (13) 7 (3.9) 2 (1.1) 9 (5)
Peripheral sensory neuropathy 36 (52.2) 3 (4.3) 39 (56.5) 101 (55.8) 14 (7.7) 115 (63.5)
Grade 3-4
Febrile neutropenia 1 (1.4) 5 (7.2) 6 (8.7) 7 (3.9) 6 (3.3) 13 (7.2)
Neutropenia 1 (1.4) 0 1 (1.4) 1 (0.6) 1 (0.6) 2 (1.1)
Anemia 1 (1.4) 4 (5.8) 5 (7.2) 2 (1.1) 8 (4.4) 10 (5.5)
Fatigue 4 (5.8) 1 (1.4) 5 (7.2) 1 (0.6) 0 1 (0.6)
Nausea 3 (4.3) 1 (1.4) 4 (5.8) 0 0 0
Vomiting 1 (1.4) 0 1 (1.4) 0 0 0
Diarrhea 3 (4.3) 2 (2.9) 5 (7.2) 3 (1.7) 1 (0.6) 4 (2.2)
Peripheral motor neuropathy 1 (1.4) 0 1 (1.4) 0 0 0
Peripheral sensory neuropathy 1 (1.4) 0 1 (1.4) 3 (1.7) 0 3 (1.7)
Adverse Events of Special Interest (Including Immune-Related Toxic Effects)
All grades
Hypothyroidism 3 (4.3) 4 (5.8) 7 (10.1) 0 0 0
Hyperthyroidism 2 (2.9) 2 (2.9) 4 (5.8) 0 0 0
Adrenal insufficiency 1 (1.4) 5 (7.2) 6 (8.7) 0 0 0
Hepatitis 1 (1.4) 1 (1.4) 2 (2.9) 0 0 0
Pneumonitis 2 (2.9) 1 (1.4) 3 (4.3) 1 (0.6) 1 (0.6) 2 (1.1)
b
b
c
d
a
b
c
d
